Skip to main content
An official website of the United States government

Investor Initiatives


2024 Application Period Opens: January 25, 2024

2024 Application Period Closes: February 22, 2024



Pitch Your Technology and Find Potential Investors

NCI SBIR is interested in connecting SBIR- and STTR-funded companies with potential investors and strategic partners. The NCI SBIR Investor Initiatives program provides selected SBIR/STTR companies with resources to present at national showcases where they can explore partnering and investment opportunities.


2024 - 2025 Program

Participation in the Investor Initiatives is determined on a competitive basis through annual applications. Submitted applications are eligible for all of NCI’s Investor Initiatives starting in late summer 2024 through spring 2025. NCI also uses the outcomes of this program to recommend companies to the NIH SEED Company Showcase Program. Based on external reviewer feedback of submitted applications, selected companies will receive financial assistance to cover presentation and registration costs at one industry-hosted investor showcase. In the last seven years, more than 240 SBIR/STTR companies were selected to participate in the program.



All small businesses that have received a Phase I NCI SBIR/STTR award in FY2022 or later or received a Phase II NCI SBIR/STTR award in FY2020 or later are eligible to apply. Please note that each company can submit only one application. If a company has received multiple awards, select the project/product with the greatest commercial potential for an investor event. Companies in all developmental stages are welcome to apply.

Please note: this application is separate from the NIH SEED Company Showcase Program application. If you are applying to these opportunities with an eligible NCI award, you must complete the NCI application. 



  • Our review team includes about 65–80 venture capitalists/strategic partners. Application reviewers qualified in your technology area may include some of the industry’s top venture capitalists and strategic partners that may be looking for deal flow. Past reviewers have included representatives from AbbVie, Bill & Melinda Gates Foundation, Johnson & Johnson, OrbiMed, Siemens, and Takeda Ventures.
  • We will provide detailed feedback based on investor reviews and discussion of your application, giving you a chance to learn how investors and strategic partners are viewing your technology.
  • NCI SBIR will use the external review to identify and recommend companies for all of NCI’s Investor Initiatives in 2024, including industry-specific showcases, depending on the technology area and your product’s developmental stage.
  • The review may also recommend that your company take part in the NCI SBIR Industry Mentoring and Assistance Program. If so, we will contact you separately about this opportunity.
  • You could receive financial assistance for presenting at investor forums.
  • Your application will inform SBIR program staff on the key parts of your technology in a way that allows us to share your company’s progress and stage with external investors.


  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Investor Initiatives was originally published by the National Cancer Institute.”